The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia

Biological Psychiatry

Volumn 46, Issue 12, 1999, Pages 1672-1681

  Sachdev, Perminder ^a   Saharov, Tanya ^b   Cathcart, Stuart ^b  

^a PRINCE HENRY HOSPITAL   (Australia)

^b NONE

Author keywords

Antioxidants; Antipsychotic drugs; Free radical injury; Selegiline; Tardive dyskinesia; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; FLUPHENAZINE DECANOATE; FREE RADICAL; NEUROLEPTIC AGENT; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MASTICATION; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SUPERSENSITIVITY; TARDIVE DYSKINESIA; TREMOR;

ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; FLUPHENAZINE; FREE RADICALS; MALE; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE; VITAMIN E;

EID: 0033437165     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00091-8     Document Type: Article

References (37)

1. Amenta F, Bongrani S, Cadel S, Ricci A, Valsecchi B, Zeng YC (1994): Neuroanatomy of aging brain. Influence of treatment with L-deprenyl. Ann NY Acad Sci 717:33-44.
2. Baskin P, Salamone J (1993): Vacuous chewing movements in rats induced by acute reserpine administrations: interactions with different doses of apomorphine. Pharmacol Biochem Behav 46:793-797.
3. Cadet JL, Lohr JB (1989): Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 570:176-185.
4. Cohen G, Spina MB (1989): Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26:689-690.
5. Egan MF, Ferguson J, Hyde TM (1996): Effects of rating parameters on assessment of neuroleptic-induced vacuous chewing movements. Pharmacol Biochem Behav 53:401-410.
6. Egan MF, Apud J, Wyatt RJ (1997): Treatment of tardive dyskinesia. Schiz Bull 23:583-609.
7. Ellison G, See R, Levin E, Kinney J (1987): Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology 92:122-126.
8. Ellison G, Johansson P, Levin E, See R, Gunne L (1988): Chronic neuroleptics alter the effects of the Dl agonist SF&F 38393 and the D2 agonist LY171555 on oral movements in rats. Psychopharmacology 96:253-257.
9. Ellison G, See R (1989): Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology 98: 564-566.
10. Gattaz WF, Emrich A, Behrens S (1991): Alpha-tocopherol protect against development of neuroleptic-induced tardive dyskinesia? Biol Psychiatry 29:4208.
11. Gattaz WF, Emrich A, Behrens S (1993): Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia. J Neural Transm 92:197-201.
12. Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA (1993): A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 33:700-706.
13. Gunne LM, Anderson U, Bondesson U, Johansson P (1986): Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 25:897-901.
14. Heinonen EH, Anttila MI, Lammintausta RAS (1994): Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742-749.
15. Kitani K, Kanai S, Carrillo MC, Ivy GO (1994): (-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats. Ann NY Acad Sci 717:60-71.
16. Klawans HL, Rubovits R (1972): An experimental model of tardive dyskinesia. J Neural Trans 33:235-246.
17. Knoll J (1989): The pharmacology of selegiline ((-)deprenyl): new aspects. Acta Neurol Scand 126:83-91.
18. 3H in rat brain. Prog Brain Res 106:144-154.
19. Monji A, Morimoto N, Okuyama I, Yamashita N, Tashiro N (1994: Effect of dietary vitamin E on lipofuscin accumulation with age in the rat brain. Brain Res 634:62-68.
20. Muller DPR, Lloyd JK, Wolff OH (1983): Vitamin E and neurologic function. Lancet 1:225-228.
21. Muller DPR, Goss-Sampson MA (1990): Neurochemical, neurophysiological and neuropathological studies in vitamin E deficiency. Crit Rev Neurobiol 5:239-263.
22. The Parkinson Study Group (1989): Effect of deprenyl on the progression of disability in early Parkinson's disease. New Eng J Med 321:1364-1371.
23. Rodriguez LA, Moss DE, Reyes E, Camarena ML (1986): Perioral behaviours induced by cholinesterase inhibitors: a controversial animal model. Pharmacol Biochem Behav 25:1217-1221.
24. Rupniak NMJ, Jenner P, Marsden CD (1985): Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats. Psychopharmacology 85: 71-79.
25. Rupniak NMJ, Tye SJ, Iversen SD (1990): Drug-induced purposeless chewing: animal model of dyskinesia or nausea? Psychopharmacology 102:325-328.
26. Salamone J, Baskin P (1996): Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Pharmacol Biochem Behav 53:179-183.
27. Smith RC (1988): Is the dopaminergic supersensitivity theory of tardive dyskinesia valid? In: Wolf ME, Mosnaim AD, Editors. Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. Washington DC: American Psychiatric Press, pp 1-22.
28. Smith RC, Tamminga CA, Haraszti J et al (1977): Effects of dopamine agonists in tardive dyskinesia. Am J Psychiatry 134:763-768.
29. Sokol RJ (1989): Vitamin E and neurologic function in man. Free Radical Biol Med 6:189-207.
30. Steinpreis RE, Salamone JD (1993): The effects of acute haloperidol and reserpine administration on vacuous jaw movements in three different age groups of rats. Pharmacol Biochem Behav 46:405-409.
31. Stoessl AJ, Dourish CT, Iversen SD (1989): Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. Psychopharmacology 98:372-379.
32. Szatmari I, Toth K (1992): Pharmacokinetics and metabolism of selegiline (review). Acta Pharmaceutica Hungarica 62:243-248.
33. Tamminag CA, Dale JM, Goodman L, Kaneda H, Kaneda N (1990): Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology 102:474-478.
34. Tetrud JW, Langston JW (1989): The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522.
35. Vatassery GT, Angerhofer CK, Peterson FJ (1984): Vitamin E concentrations in the brains and some selected peripheral tissues of selenium-deficient and vitamin E-deficient mice. J Neurochem 42:554-558.
36. Waddington JL (1990): Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101: 431-447.
37. Waddington JL, Molloy AG, O'Boyle KM (1988): Behavioral effects of long-term treatment with further typical neuroleptics and selective D-2 dopamine receptor antagonists in young vs. aged animals. In: Sandler M, Dahlstrom A, Belmaker R, Editors. Progress in Catecholamine Research. Part B: Central Aspects. New York: Liss, pp 43-46.